Mark Floyd Lew, MD

Title(s)Professor of Clinical Neurology
SchoolKeck School of Medicine of Usc
AddressHCC 3000 1520 San Pablo Street
Health Sciences Campus
Los Angeles CA 90033
Phone+1 323 442 5728
vCardDownload vCard
    Other Positions
    Title(s)Joseph P. Van Der Meulen, M.D. Chair in Parkinson's Disease Research in Honor of Robert J. Pasarow

    Title(s)Vice Chair, Department of Neurology

    Title(s)Division Chief, Movement Disorders


    Collapse Overview 
    Collapse Overview
    Dr. Lew has an international reputation for the treatment of patients with Parkinson’s disease, dystonia, and other movement disorders. He is a board certified neurologist and a fellow of the American Academy of Neurology. Dr. Lew is the director of the Division of Movement Disorders and serves as the vice chairman of the Department of Neurology. He has lectured extensively in the United States and abroad on clinical research related to new therapies for Parkinson’s disease and dystonia. Dr. Lew also collaborates closely with local and national advocacy organizations (e.g., the Hollyrod Foundation and the National Parkinson’s Foundation) to increase public awareness and to support research and care.

    Collapse Research 
    Collapse Research Activities and Funding
    Neuroprotective Clinical Studies in Parkinson's Disease
    NIH U10NS044462Sep 15, 2002 - Nov 30, 2015
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. BoNT clinical trial update: Sialorrhea. Toxicon. 2023 Apr; 226:107087. Tamadonfar ET, Lew MF. PMID: 36931440.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Should "on-demand" treatments for Parkinson's disease OFF episodes be used earlier? Clin Park Relat Disord. 2022; 7:100161. Isaacson SH, Pagan FL, Lew MF, Pahwa R. PMID: 36033905; PMCID: PMC9405081.
      View in: PubMed   Mentions: 3  
    3. AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions. Clin Park Relat Disord. 2021; 5:100115. Lew MF, Hauser RA, Isaacson SH, Truong D, Patel AT, Brashear A, Ondo W, Maisonobe P, Dashtipour K, Bahroo L, Wietek S. PMID: 34888518; PMCID: PMC8636802.
      View in: PubMed   Mentions:
    4. Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study. PLoS One. 2021; 16(4):e0250475. Patel AT, Lew MF, Dashtipour K, Isaacson S, Hauser RA, Ondo W, Maisonobe P, Wietek S, Rubin B, Brashear A. PMID: 33852647; PMCID: PMC8046252.
      View in: PubMed   Mentions:    Fields:    
    5. Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study. PLoS One. 2021; 16(2):e0245827. Patel AT, Lew MF, Dashtipour K, Isaacson S, Hauser RA, Ondo W, Maisonobe P, Wietek S, Rubin B, Brashear A. PMID: 33524060; PMCID: PMC7850472.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    6. Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor. Tremor Other Hyperkinet Mov (N Y). 2020 08 14; 10:29. Isaacson SH, Peckham E, Tse W, Waln O, Way C, Petrossian MT, Dahodwala N, Soileau MJ, Lew M, Dietiker C, Luthra N, Agarwal P, Dhall R, Morgan J, Calakos N, Zesiewicz TA, Shamim EA, Kumar R, LeWitt P, Shill HA, Simmons A, Pagan FL, Khemani P, Tate J, Maddux B, Luo L, Ondo W, Hallett M, Rajagopal A, Chidester P, Rosenbluth KH, Delp SL, Pahwa R. PMID: 32864188; PMCID: PMC7427656.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    7. Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial. JAMA Neurol. 2020 04 01; 77(4):461-469. Isaacson SH, Ondo W, Jackson CE, Trosch RM, Molho E, Pagan F, Lew M, Dashtipour K, Clinch T, Espay AJ, MYSTICOL Study Group. PMID: 31930364; PMCID: PMC6990829.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    8. Tears - more to them than meets the eye: why tears are a good source of biomarkers in Parkinson's disease. Biomark Med. 2020 02; 14(2):151-163. Edman MC, Janga SR, Kakan SS, Okamoto CT, Freire D, Feigenbaum D, Lew M, Hamm-Alvarez SF. PMID: 32064896.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    9. Levels of oligomeric α-Synuclein in reflex tears distinguish Parkinson's disease patients from healthy controls. Biomark Med. 2019 12; 13(17):1447-1457. Hamm-Alvarez SF, Janga SR, Edman MC, Feigenbaum D, Freire D, Mack WJ, Okamoto CT, Lew MF. PMID: 31552762.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    10. Targeting neurons in the gastrointestinal tract to treat Parkinson's disease. Clin Park Relat Disord. 2019; 1:2-7. Hauser RA, Sutherland D, Madrid JA, Rol MA, Frucht S, Isaacson S, Pagan F, Maddux BN, Li G, Tse W, Walter BL, Kumar R, Kremens D, Lew MF, Ellenbogen A, Oguh O, Vasquez A, Kinney W, Lowery M, Resnick M, Huff N, Posner J, Ballman KV, Harvey BE, Camilleri M, Zasloff M, Barbut D. PMID: 34316590; PMCID: PMC8288812.
      View in: PubMed   Mentions: 7  
    11. Oligomeric α-synuclein is increased in basal tears of Parkinson's patients. Biomark Med. 2019 08; 13(11):941-952. Hamm-Alvarez SF, Okamoto CT, Janga SR, Feigenbaum D, Edman MC, Freire D, Shah M, Ghanshani R, Mack WJ, Lew MF. PMID: 31262201.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    12. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019 02; 18(2):145-154. LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C, SPAN-PD Study Investigators. PMID: 30663606.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    13. Use of botulinum toxin in Parkinson's disease. Parkinsonism Relat Disord. 2019 02; 59:57-64. Jocson A, Lew M. PMID: 30579818.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    14. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease. Mov Disord. 2018 Jul; 33(6):928-936. Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, Standaert DG, Zadikoff C, Vanagunas AD, Chatamra K, Eaton S, Facheris MF, Hall C, Robieson WZ, Benesh J, Espay AJ. PMID: 29570853.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    15. A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. Int J Neurosci. 2018 Jul; 128(7):619-626. Lew MF, Brashear A, Dashtipour K, Isaacson S, Hauser RA, Maisonobe P, Snyder D, Ondo W. PMID: 29343142.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    16. Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease. Clin Auton Res. 2017 07; 27(Suppl 1):5-7. Lew M, Kremens D. PMID: 28674866; PMCID: PMC5524847.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease. Clin Auton Res. 2017 07; 27(Suppl 1):29-31. Kremens D, Lew M, Claassen D, Goodman BP. PMID: 28674867; PMCID: PMC5524861.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    18. Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease. Clin Auton Res. 2017 07; 27(Suppl 1):13-14. Claassen D, Lew M. PMID: 28631224; PMCID: PMC5524864.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    19. Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension. Clin Auton Res. 2017 07; 27(Suppl 1):35-37. Vernino S, Lew M, Kremens D. PMID: 28623420; PMCID: PMC5524870.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials. J Clin Mov Disord. 2017; 4:9. Dashtipour K, Bhidayasiri R, Chen JJ, Jabbari B, Lew M, Torres-Russotto D. PMID: 28593050; PMCID: PMC5460542.
      View in: PubMed   Mentions: 7  
    21. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease. Mov Disord. 2017 05; 32(5):783-789. Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA, Klepiskaya OS, Kreitzman DL, Lew MF, Russell DS, Kadosh S, Litman P, Friedman H, Linvah N, The P B Study Group F. PMID: 28370340.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    22. Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry. J Neurol Sci. 2017 May 15; 376:84-90. Trosch RM, Espay AJ, Truong D, Gil R, Singer C, LeWitt PA, Lew MF, Tagliati M, Adler CH, Chen JJ, Marchese D, Comella CL. PMID: 28431634.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    23. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017 Aug; 264(8):1567-1582. Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, Karabin B, Kuritzky L, Lew M, Low P, Mehdirad A, Raj SR, Vernino S, Kaufmann H. PMID: 28050656; PMCID: PMC5533816.
      View in: PubMed   Mentions: 116     Fields:    Translation:Humans
    24. Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective. Expert Rev Neurother. 2017 03; 17(3):219-225. Isaacson SH, Fisher S, Gupta F, Hermanowicz N, Kremens DE, Lew MF, Marek K, Pahwa R, Russell DS, Seibyl J. PMID: 27813429.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    25. Poster 290 Efficacy and Safety of a 2 mL Dilution of AbobotulinumtoxinA Compared with Placebo in Adult Patients with Cervical Dystonia. PM R. 2016 Sep; 8(9S):S254-S255. Lew MF, Camba GC, Snyder D. PMID: 27673045.
      View in: PubMed   Mentions: 1     Fields:    
    26. Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease. Mov Disord Clin Pract. 2017 Jan-Feb; 4(1):78-83. Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F. PMID: 28239615; PMCID: PMC5298032.
      View in: PubMed   Mentions: 22  
    27. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 09; 31(9):1373-80. Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O. PMID: 27214664.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    28. Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Mov Disord. 2016 Apr; 31(4):538-46. Lang AE, Rodriguez RL, Boyd JT, Chouinard S, Zadikoff C, Espay AJ, Slevin JT, Fernandez HH, Lew MF, Stein DA, Odin P, Fung VS, Klostermann F, Fasano A, Draganov PV, Schmulewitz N, Robieson WZ, Eaton S, Chatamra K, Benesh JA, Dubow J. PMID: 26695437; PMCID: PMC5064722.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    29. Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. Parkinsonism Relat Disord. 2015 Jul; 21(7):742-8. Lew MF, Slevin JT, Krüger R, Martínez Castrillo JC, Chatamra K, Dubow JS, Robieson WZ, Benesh JA, Fung VS. PMID: 25962554.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    30. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM. PMID: 25668262; PMCID: PMC4349346.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    31. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord. 2015 Apr; 30(4):500-9. Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ. PMID: 25545465; PMCID: PMC4674978.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCTClinical Trials
    32. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug; 13(8):767-76. Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O, Neale A, Resburg C, Meya U, Kenney C, Bandak S. PMID: 25008546.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCTClinical Trials
    33. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014 May; 71(5):543-52. Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K. PMID: 24664227.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansCTClinical Trials
    34. Rasagiline treatment effects on parkinsonian tremor. Int J Neurosci. 2013 Dec; 123(12):859-65. Lew MF. PMID: 23767986.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    35. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol. 2012 Sep-Oct; 35(5):215-23. Chinnapongse RB, Lew MF, Ferreira JJ, Gullo KL, Nemeth PR, Zhang Y. PMID: 22932474.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    36. Accuracy and sensitivity of Parkinsonian disorder diagnoses in two Swedish national health registers. Neuroepidemiology. 2012; 38(3):186-93. Feldman AL, Johansson AL, Gatz M, Flensburg M, Petzinger GM, Widner H, Lew MF, Pedersen NL, Wirdefeldt K. PMID: 22472568; PMCID: PMC3375128.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    37. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off. Int J Neurosci. 2011 Nov; 121(11):605-13. Lew MF, Somogyi M, McCague K, Welsh M, Lce QoL Study Group. PMID: 21843110.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    38. Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease. Int J Neurosci. 2011 May; 121(5):246-53. Hauser RA, Reichmann H, Lew M, Asgharian A, Makumi C, Shulman KJ. PMID: 21244307.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    39. The evidence for disease modification in Parkinson's disease. Int J Neurosci. 2011; 121 Suppl 2:18-26. Lew MF. PMID: 22035026.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    40. Polycythemia and chorea. Handb Clin Neurol. 2011; 100:271-6. Marvi MM, Lew MF. PMID: 21496586.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    41. Long-term efficacy of rasagiline in early Parkinson's disease. Int J Neurosci. 2010 Jun; 120(6):404-8. Lew MF, Hauser RA, Hurtig HI, Ondo WG, Wojcieszek J, Goren T, Fitzer-Attas CJ. PMID: 20504210.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    42. RimabotulinumtoxinB effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studies. Int J Neurosci. 2010 Apr; 120(4):298-300. Lew MF, Chinnapongse R, Zhang Y, Corliss M. PMID: 20374078.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    43. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun; 16(5):316-23. Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S, Global Dysport Cervical Dystonia Study Group. PMID: 20359934.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    44. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol. 2010 Mar; 67(3):347-52. Bertoni JM, Arlette JP, Fernandez HH, Fitzer-Attas C, Frei K, Hassan MN, Isaacson SH, Lew MF, Molho E, Ondo WG, Phillips TJ, Singer C, Sutton JP, Wolf JE, North American Parkinson's and Melanoma Survey Investigators. PMID: 20212233.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    45. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol. 2010 Jan-Feb; 33(1):5-10. Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R. PMID: 19855267.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    46. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009 Mar 15; 24(4):564-73. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ, TEMPO Open-label Study Group. PMID: 19086083.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    47. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med. 2008 Nov 05; 6:32. Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Goldwurm S, Pezzoli G, Zini M, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Laramie JM, DeStefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. PMID: 18986508; PMCID: PMC2596771.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    48. Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord. 2008 Aug 15; 23(11):1596-601. McNicoll CF, Latourelle JC, MacDonald ME, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Saint-Hilaire MH, Massood T, Huskey KW, DeStefano AL, Gillis T, Mysore J, Goldwurm S, Pezzoli G, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. PMID: 18649400; PMCID: PMC2655323.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    49. Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Hum Genet. 2008 Aug; 124(1):95-9. DeStefano AL, Latourelle J, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts R, Guttman M, Racette BA, Perlmutter JS, Marlor L, Shill HA, Singer C, Goldwurm S, Pezzoli G, Saint-Hilaire MH, Hendricks AE, Gower A, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. PMID: 18587682; PMCID: PMC2716559.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    50. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology. 2008 Jul 01; 71(1):28-34. Tobin JE, Latourelle JC, Lew MF, Klein C, Suchowersky O, Shill HA, Golbe LI, Mark MH, Growdon JH, Wooten GF, Racette BA, Perlmutter JS, Watts R, Guttman M, Baker KB, Goldwurm S, Pezzoli G, Singer C, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Laramie JM, DeStefano AL, Litvan I, Nicholson G, Corbett A, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Sherman S, Al-hinti J, Drasby E, Nance M, Moller AT, Ostergaard K, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. PMID: 18509094; PMCID: PMC2654275.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    51. Role of botulinum toxin in the treatment of cervical dystonia. Neurol Clin. 2008 May; 26 Suppl 1:43-53. Molho E, Jankovic J, Lew M. PMID: 18603167.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    52. Overview of Parkinson's disease. Pharmacotherapy. 2007 Dec; 27(12 Pt 2):155S-160S. Lew M. PMID: 18041935.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    53. Results from a 2-year centralized tolcapone liver enzyme monitoring program. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):281-6. Lew MF, Kricorian G. PMID: 17909306.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    54. Complete ascertainment of Parkinson disease in the Swedish Twin Registry. Neurobiol Aging. 2008 Dec; 29(12):1765-73. Wirdefeldt K, Gatz M, Bakaysa SL, Fiske A, Flensburg M, Petzinger GM, Widner H, Lew MF, Welsh M, Pedersen NL. PMID: 17532098; PMCID: PMC2662365.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    55. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. Curr Med Res Opin. 2007 Apr; 23(4):741-50. Lew MF, Pahwa R, Leehey M, Bertoni J, Kricorian G, Zydis Selegiline Study Group. PMID: 17407630.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    56. Calcification of the Basal Ganglia. Handb Clin Neurol. 2007; 84:479-86. Hui JS, Lew MF. PMID: 18808965.
      View in: PubMed   Mentions: 1     Fields:    
    57. Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study. Neurology. 2006 Dec 26; 67(12):2206-10. Wilk JB, Tobin JE, Suchowersky O, Shill HA, Klein C, Wooten GF, Lew MF, Mark MH, Guttman M, Watts RL, Singer C, Growdon JH, Latourelle JC, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Berg CJ, Sun M, Goldwurm S, Pezzoli G, Racette BA, Perlmutter JS, Parsian A, Baker KB, Giroux ML, Litvan I, Pramstaller PP, Nicholson G, Burn DJ, Chinnery PF, Vieregge P, Slevin JT, Cambi F, MacDonald ME, Gusella JF, Myers RH, Golbe LI. PMID: 17190945.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansPHPublic Health
    58. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol. 2006 Jun; 63(6):826-32. Sun M, Latourelle JC, Wooten GF, Lew MF, Klein C, Shill HA, Golbe LI, Mark MH, Racette BA, Perlmutter JS, Parsian A, Guttman M, Nicholson G, Xu G, Wilk JB, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Suchowersky O, Labelle N, Growdon JH, Singer C, Watts RL, Goldwurm S, Pezzoli G, Baker KB, Pramstaller PP, Burn DJ, Chinnery PF, Sherman S, Vieregge P, Litvan I, Gillis T, MacDonald ME, Myers RH, Gusella JF. PMID: 16769863.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    59. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study. Neurology. 2005 Dec 13; 65(11):1823-5. Karamohamed S, Latourelle JC, Racette BA, Perlmutter JS, Wooten GF, Lew M, Klein C, Shill H, Golbe LI, Mark MH, Guttman M, Nicholson G, Wilk JB, Saint-Hilaire M, DeStefano AL, Prakash R, Tobin S, Williamson J, Suchowersky O, Labell N, Growdon BN, Singer C, Watts R, Goldwurm S, Pezzoli G, Baker KB, Giroux ML, Pramstaller PP, Burn DJ, Chinnery P, Sherman S, Vieregge P, Litvan I, Gusella JF, Myers RH, Parsian A. PMID: 16344533.
      View in: PubMed   Mentions: 25     Fields:    
    60. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease. Expert Rev Neurother. 2005 Nov; 5(6):705-12. Lew MF. PMID: 16274328.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study. Mov Disord. 2005 Sep; 20(9):1188-91. Karamohamed S, Golbe LI, Mark MH, Lazzarini AM, Suchowersky O, Labelle N, Guttman M, Currie LJ, Wooten GF, Stacy M, Saint-Hilaire M, Feldman RG, Liu J, Shoemaker CM, Wilk JB, DeStefano AL, Latourelle JC, Xu G, Watts R, Growdon J, Lew M, Waters C, Vieregge P, Pramstaller PP, Klein C, Racette BA, Perlmutter JS, Parsian A, Singer C, Montgomery E, Baker K, Gusella JF, Herbert A, Myers RH. PMID: 15966003.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    62. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul; 20(7):783-91. Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL. PMID: 15736159.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCTClinical Trials
    63. Behavioral changes as side effects of medication treatment for Parkinson's disease. Adv Neurol. 2005; 96:114-29. Hui JS, Murdock GA, Chung JS, Lew MF. PMID: 16383216.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    64. Duration of effectiveness of botulinum toxin type B in the treatment of cervical dystonia. Adv Neurol. 2004; 94:211-5. Lew MF. PMID: 14509675.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    65. A haplotype at the PARK3 locus influences onset age for Parkinson's disease: the GenePD study. Neurology. 2003 Dec 09; 61(11):1557-61. Karamohamed S, DeStefano AL, Wilk JB, Shoemaker CM, Golbe LI, Mark MH, Lazzarini AM, Suchowersky O, Labelle N, Guttman M, Currie LJ, Wooten GF, Stacy M, Saint-Hilaire M, Feldman RG, Sullivan KM, Xu G, Watts R, Growdon J, Lew M, Waters C, Vieregge P, Pramstaller PP, Klein C, Racette BA, Perlmutter JS, Parsian A, Singer C, Montgomery E, Baker K, Gusella JF, Fink SJ, Myers RH, Herbert A, GenePD study. PMID: 14663042.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    66. Gait and Balance Dysfunction in Adults. Curr Treat Options Neurol. 2003 Mar; 5(2):177-185. Manek S, Lew MF. PMID: 12628066.
      View in: PubMed   Mentions: 1  
    67. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain. 2002 Nov-Dec; 18(6 Suppl):S142-6. Lew MF. PMID: 12569961.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    68. PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet. 2002 May; 70(5):1089-95. DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF, Maher NE, Wilk JB, Sullivan KM, Slater KM, Saint-Hilaire MH, Feldman RG, Suchowersky O, Lafontaine AL, Labelle N, Growdon JH, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Reider CR, Stacy M, MacDonald ME, Gusella JF, Myers RH. PMID: 11920285; PMCID: PMC447587.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    69. Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study. Neurology. 2002 Jan 08; 58(1):79-84. Maher NE, Golbe LI, Lazzarini AM, Mark MH, Currie LJ, Wooten GF, Saint-Hilaire M, Wilk JB, Volcjak J, Maher JE, Feldman RG, Guttman M, Lew M, Waters CH, Schuman S, Suchowersky O, Lafontaine AL, Labelle N, Vieregge P, Pramstaller PP, Klein C, Hubble J, Reider C, Growdon J, Watts R, Montgomery E, Baker K, Singer C, Stacy M, Myers RH. PMID: 11781409.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    70. Botulinum toxin type B: An effective treatment for alleviating pain associated with cervical dystonia. J Back Musculoskelet Rehabil. 2002 Jan 01; 16(1):3-9. Lew MF. PMID: 22387358.
      View in: PubMed   Mentions: 1     Fields:    
    71. Botulinum toxin type B (Myobloc, NeuroBloc): a new choice in cervical dystonia. Expert Rev Neurother. 2001 Nov; 1(2):143-52. Lew MF. PMID: 19811026.
      View in: PubMed   Mentions: 1     Fields:    
    72. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology. 2001 Feb 27; 56(4):455-62. Shoulson I, Penney J, McDermott M, Schwid S, Kayson E, Chase T, Fahn S, Greenamyre JT, Lang A, Siderowf A, Pearson N, Harrison M, Rost E, Colcher A, Lloyd M, Matthews M, Pahwa R, McGuire D, Lew MF, Schuman S, Marek K, Broshjeit S, Factor S, Brown D, Feigin A, Mazurkiewicz J, Ford B, Jennings D, Dilllon S, Comella C, Blasucci L, Janko K, Shulman L, Wiener W, Bateman-Rodriguez D, Carrion A, Suchowersky O, Lafontaine AL, Pantella C, Siemers E, Belden J, Davies R, Lannon M, Grimes D, Gray P, Martin W, Kennedy L, Adler C, Newman S, Hammerstad J, Stone C, Lewitt P, Bardram K, Mistura K, Miyasaki J, Johnston L, Cha JH, Tennis M, Panniset M, Hall J, Tetrud J, Friedlander J, Hauser R, Gauger L, Rodnitzky R, Deleo A, Dobson J, Seeberger L, Dingmann C, Tarsy D, Ryan P, Elmer L, Ruzicka D, Stacy M, Brewer M, Locke B, Baker D, Casaceli C, Day D, Florack M, Hodgeman K, Laroia N, Nobel R, Orme C, Rexo L, Rothenburgh K, Sulimowicz K, Watts A, Wratni E, Tariot P, Cox C, Leventhal C, Alderfer V, Craun AM, Frey J, McCree L, McDermott J, Cooper J, Holdich T, Read B, Parkinson Study Group. PMID: 11222787.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    73. Current and emerging treatments for cervical dystonia. CNS Spectr. 2000 Jun; 5(6 Suppl 5):S1-8. Factor SA, Lew MF, Trosch RM. PMID: 18268461.
      View in: PubMed   Mentions:    Fields:    
    74. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology. 2000; 55(12 Suppl 5):S29-35. Lew MF, Brashear A, Factor S. PMID: 11188982.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    75. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999 Oct 22; 53(7):1439-46. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. PMID: 10534248.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    76. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22; 53(7):1431-8. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. PMID: 10534247.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    77. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol. 1998 Aug; 55(8):1089-95. Adler CH, Singer C, O'Brien C, Hauser RA, Lew MF, Marek KL, Dorflinger E, Pedder S, Deptula D, Yoo K. PMID: 9708959.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    78. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997 Sep; 49(3):701-7. Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, Brin MF, Jankovic J, Rodnitzky RL, Singer C, Swenson MR, Tarsy D, Murray JJ, Koller M, Wallace JD. PMID: 9305326.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    79. Ventroposterior medial pallidotomy in patients with advanced Parkinson's disease. Neurosurgery. 1995 Jun; 36(6):1112-6; discussion 1116-7. Sutton JP, Couldwell W, Lew MF, Mallory L, Grafton S, DeGiorgio C, Welsh M, Apuzzo ML, Ahmadi J, Waters CH. PMID: 7643989.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    80. Pallidotomy increases activity of motor association cortex in Parkinson's disease: a positron emission tomographic study. Ann Neurol. 1995 Jun; 37(6):776-83. Grafton ST, Waters C, Sutton J, Lew MF, Couldwell W. PMID: 7778851.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    81. Adductor laryngeal breathing dystonia in a patient with lubag (X-linked dystonia-Parkinsonism syndrome). Mov Disord. 1994 May; 9(3):318-20. Lew MF, Shindo M, Moskowitz CB, Wilhelmsen KC, Fahn S, Waters CH. PMID: 8041372.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    82. Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc. 1993 Jun; 41(6):669-71. Lew MF, Waters CH. PMID: 8505467.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    83. Consciousness, coma, and the vegetative state: physical basis and definitional character. Issues Law Med. 1991; 6(4):361-71. De Giorgio CM, Lew MF. PMID: 2037460.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    See more options in the Advanced Search tab

    Mark's Networks
    Concepts (289)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (16)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-2-gbbe5f151 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.